A-101

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Seborrheic Keratosis

Conditions

Seborrheic Keratosis

Trial Timeline

May 17, 2017 → Apr 3, 2018

NCT ID

NCT03148691

About A-101

A-101 is a phase 2 stage product being developed by Aclaris Therapeutics for Seborrheic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03148691. Target conditions include Seborrheic Keratosis.

What happened to similar drugs?

2 of 6 similar drugs in Seborrheic Keratosis were approved

Approved (2) Terminated (0) Active (4)

✅KetoconazoleGSK plcApproved

🔄Roflumilast Foam + Vehicle FoamArcutis BiotherapeuticsPhase 3

🔄A-101 SolutionAclaris TherapeuticsPhase 3

✅A-101 Topical SolutionAclaris TherapeuticsApproved

🔄A-101 SolutionAclaris TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03812510	Phase 3	Completed	Feb 7, 2019	Dec 20, 2019	Common Wart
NCT03687372	Phase 3	Completed	Sep 17, 2018	Sep 6, 2019	Common Wart
NCT03148691	Phase 2	Completed	May 17, 2017	Apr 3, 2018	Seborrheic Keratosis
NCT02260180	Phase 2	Completed	Oct 1, 2014	Mar 1, 2015	Seborrheic Keratosis

Competing Products

15 competing products in Seborrheic Keratosis

See all competitors

Product	Company	Stage	Hype Score
Elidel + Ketoconazole Cream	Novartis	Phase 2	35
PF-07038124 + Placebo Ointment	Pfizer	Phase 2	27
Ketoconazole	GSK plc	Approved	43
Azelaic Acid 15% Gel + Inactive 15% gel base	Bayer	Phase 2	32
Ruxolitinib 1.5% Cream	Incyte	Phase 2	32
Roflumilast Foam 0.3% + Vehicle foam	Arcutis Biotherapeutics	Phase 2	29
Roflumilast Foam + Vehicle Foam	Arcutis Biotherapeutics	Phase 3	34
ARQ-154	Arcutis Biotherapeutics	Phase 2	29
A-101 Solution	Aclaris Therapeutics	Phase 3	30
A-101 Solution	Aclaris Therapeutics	Phase 3	30
A-101 Topical Solution	Aclaris Therapeutics	Approved	33
A-101	Aclaris Therapeutics	Phase 2	25
A-101 Solution	Aclaris Therapeutics	Phase 3	30
A-101 25% + A-101 32.5% + A-101 40% + A-101 Vehicle	Aclaris Therapeutics	Phase 1/2	22
A-101 Vehicle + A-101 (40) Topical Solution + A-101 (32.5) Topical Solution	Aclaris Therapeutics	Phase 2	25